Schrodinger, Inc. SDGR

The low purchase price of Helomics and low revenue suggest that the acquisition is not that promising for DataMEDS AI.

NEW YORK, September 17, 2026--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on September 13, 2026, the company granted restricted stock units (RSUs) with respect to 2,243 shares of the company’s common stock to three newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company’s board of directors, and were made as a material induc

NEW YORK, September 09, 2026--Schrödinger announced the formation of Tectora, a biotech it co-founded with NEA and RA Capital, focused on immunology and inflammation therapies.

Equity Insider News Commentary - Pharmaceutical research is being rebuilt around artificial intelligence faster than the industry can absorb it. Arizton values the global AI in drug discovery market at approximately $1.71 billion in 2024 and projects it will reach roughly $8.52 billion by 2030, a compound annual growth rate of about 30.58%. That is a market compounding at more than double the rate of most enterprise software categories, and it is being spent inside an industry that already inves

NEW YORK, September 01, 2026--Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference. The live presentation will take place on Monday, September 14, 2026 at 1:05 p.m. E.T.

Anthropic is racing toward a public debut in September with a healthcare AI pitch that could ignite a sector most investors are not watching. Five biotech names are already moving, and one has climbed nearly 400% in the past year alone.